Selection of fractionation regimens of stereotactic body radiotherapy in patients with early stage lung cancer
https://doi.org/10.18027/2224-5057-2023-13-1-30-35
Abstract
Stereotactic body radiotherapy for early stage non-small-cell lung cancer was, is, and will remain the key subject of discussions between radiation oncologists and surgeons. Despite the positive treatment outcomes reported in some large studies on efficacy of the stereotactic radiotherapy, its use instead of surgery may not always be an unconditional decision. However, stereotactic radiotherapy opens new treatment options in patients who are inoperable or refused surgery. This is possibly due to the high accuracy of modern linear accelerators, which allow to reduce the toxicity of radiotherapy and achieve an almost identical overall survival rate compared to surgery.
About the Authors
Yu. I. Bart
N. N. Blokhin National Research Center of Oncology
Russian Federation
Russian Federation
Yulia I. Bart, radiation therapist
Moscow
D. A. Glibichuk
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Dmitry A. Glibichuk, post-graduate student, Department of Oncology
Moscow
R. Sh. Abdulaeva
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Rukiyat Sh. Abdulaeva, second-year resident, Department of Oncology and Radiotherapy
Moscow
M. V. Chernykh
N. N. Blokhin National Research Center of Oncology;
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Marina V. Chernykh, MD, PhD, Head of the Radiotherapy Department, Deputy Medical Director; Associate Professor of the Department of Oncology, Radiotherapy and Plastic Surgery
Moscow
А. Е. Kalinin
N. N. Blokhin National Research Center of Oncology
Russian Federation
Russian Federation
Alexey E. Kalinin, MD, PhD, Senior Researcher, Acting Head of the Department of Abdominal Surgical Oncology No. 6
Moscow
T. N. Borisova
N. N. Blokhin National Research Center of Oncology
Russian Federation
Russian Federation
Tatiana N. Borisova, MD, PhD, Senior Research Scientist of the Radiation Therapy Department
Moscow
References
1. Ettinger D., Wood D., Aisner D., and Akerley W., NCCN Guidelines Non-Small Cell Lung Cancer Version 5.2022, https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450, 2022.
2. O. Cho, Y. T. Oh, M. Chun, O. K. Noh, and J. S. Heo, Prognostic implication of FEV1 / FVC ratio for limited-stage small cell lung cancer, J Thorac Dis, vol. 10, no. 3, pp. 1797–1805, Mar. 2018, doi:10.21037/jtd.2018.02.14.
3. D. J. Raz, J. A. Zell, S. H. I. Ou, D. R. Gandara, H. Anton-Culver, and D. M. Jablons, Natural history of stage I nonsmall cell lung cancer: Implications for early detection, Chest, vol. 132, no. 1, pp. 193–199, 2007, doi:10.1378/chest.06–3096.
4. J. D. Cox, J. Stetz, and T. F. Pajak, toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC), 1995.
5. P. Lee et al., Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer, Int J Radiat Oncol Biol Phys, vol. 110, no. 1, pp. 160–171, May 2021, doi:10.1016/j.ijrobp.2019.03.045.
6. R. D. Timmerman et al., Long-Term results of stereotactic body radiation therapy in medically inoperable stage i non-small cell lung cancer, JAMA Oncology, vol. 4, no. 9. American Medical Association, pp. 1287–1288, Sep. 01, 2018. doi:10.1001/jamaoncol.2018.1258.
7. H. Chen et al., Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review, International Journal of Radiation Oncology Biology Physics, vol. 98, no. 3. Elsevier Inc., pp. 622–631, Jul. 01, 2017. doi:10.1016/j.ijrobp.2017.03.010.
8. R. Timmerman et al., Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer, JAMA Oncol, vol. 303, no. 11, p. 1070, 2010, doi:10.1001/jama.2010.261.
9. Ассоциация онкологов России, Злокачественное новообразование бронхов и легкого, Клинические рекомендации, 2021.
10. G. M. M. Videtic et al., Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline, Pract Radiat Oncol, vol. 7, no. 5, pp. 295–301, Sep. 2017, doi:10.1016/j.prro.2017.04.014.
11. N. Shaverdian, P. C. Wang, M. Steinberg, and P. Lee, The patient’s perspective on stereotactic body radiation therapy (SBRT) vs. surgery for treatment of early stage non-small cell lung cancer (NSCLC), Lung Cancer, vol. 90, no. 2, pp. 230–233, Nov. 2015, doi:10.1016/j.lungcan.2015.07.009.
12. R. Timmerman et al., Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer, Journal of Clinical Oncology, vol. 24, no. 30, pp. 4833–4839, Oct. 2006, doi:10.1200/JCO.2006.07.5937.
13. M. Trovo, A. Linda, I. el Naqa, C. Javidan-Nejad, and J. Bradley, Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT), Lung Cancer, vol. 69, no. 1, pp. 77–85, Jul. 2010, doi:10.1016/j.lungcan.2009.09.006.
14. M. Guckenberger et al., Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer, Int J Radiat Oncol Biol Phys, vol. 85, no. 4, pp. 1074–1081, Mar. 2013, doi:10.1016/j.ijrobp.2012.09.016.
15. NCI, Common Terminology Criteria for Adverse Events (CTCAE) v3.0, https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf, 2006.
16. Y. Xiao et al., Dosimetric Evaluation of Heterogeneity Corrections for RTOG 0236: Stereotactic Body Radiotherapy of Inoperable Stage I-II Non–Small-Cell Lung Cancer, International Journal of Radiation Oncology*Biology*Physics, vol. 73, no. 4, pp. 1235–1242, Mar. 2009, doi:10.1016/j.ijrobp.2008.11.019.
17. J. Nyman et al., SPACE – A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC, Radiotherapy and Oncology, vol. 121, no. 1, pp. 1–8, Oct. 2016, doi:10.1016/j.radonc.2016.08.015.
18. H. West and J. O. Jin, Performance status in patients with cancer, JAMA Oncology, vol. 1, no. 7. American Medical Association, p. 998, Oct. 01, 2015. doi:10.1001/jamaoncol.2015.3113.
19. A. Bezjak et al., Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology / RTOG 0813 Trial, 2019. Accessed: Nov. 08, 2022. [Online]. Available: https://doi.org/10.1200/JCO.18.00622.
20. T. K. Nguyen et al., Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study, Pract Radiat Oncol, vol. 8, no. 2, pp. e71–e78, Mar. 2018, doi:10.1016/j.prro.2017.10.008.
21. R. Cooke et al., Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomes, Tech Innov Patient Support Radiat Oncol, vol. 13, pp. 24–30, Mar. 2020, doi:10.1016/j.tipsro.2020.01.002.
Review
For citations:
Bart Yu. ., Glibichuk D.A., Abdulaeva R.Sh., Chernykh M.V., Kalinin А.Е., Borisova T.N. Selection of fractionation regimens of stereotactic body radiotherapy in patients with early stage lung cancer. Malignant tumours. 2023;13(1):30-35. (In Russ.) https://doi.org/10.18027/2224-5057-2023-13-1-30-35
Views:
523
Email this article 